+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Respiratory Drugs Market Research Reports

Pulmonary Sarcoidosis - Epidemiology Forecast to 2032 - Product Thumbnail Image

Pulmonary Sarcoidosis - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Lung Fibrosis- Epidemiology Forecast to 2032 - Product Thumbnail Image

Lung Fibrosis- Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Malignant Pleural Effusion - Epidemiology Forecast to 2032 - Product Thumbnail Image

Malignant Pleural Effusion - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Meconium Aspiration Syndrome - Epidemiology Forecast to 2032 - Product Thumbnail Image

Meconium Aspiration Syndrome - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
From
From
Sleep Apnea - Pipeline Insight, 2024 - Product Thumbnail Image

Sleep Apnea - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Cystic Fibrosis - Pipeline Insight, 2024 - Product Thumbnail Image

Cystic Fibrosis - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 200 Pages
  • Global
From
Pertussis - Pipeline Insight, 2024 - Product Thumbnail Image

Pertussis - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 70 Pages
  • Global
From
Ventilator Associated Pneumonia (VAP) - Pipeline Insight, 2024 - Product Thumbnail Image

Ventilator Associated Pneumonia (VAP) - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Acute Lung Injury - Pipeline Insight, 2024 - Product Thumbnail Image

Acute Lung Injury - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Alpha- Antitrypsin Deficiency - Pipeline Insight, 2024 - Product Thumbnail Image

Alpha- Antitrypsin Deficiency - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Tuberculosis - Pipeline Insight, 2024 - Product Thumbnail Image

Tuberculosis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Nosocomial Pneumonia - Pipeline Insight, 2024 - Product Thumbnail Image

Nosocomial Pneumonia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
ARDS - Pipeline Insight, 2024 - Product Thumbnail Image

ARDS - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Pneumonia, Pneumococcal - Pipeline Insight, 2024 - Product Thumbnail Image

Pneumonia, Pneumococcal - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 80 Pages
  • Global
From
Pseudomonas Aeruginosa-Induced Lung Injury - Pipeline Insight, 2024 - Product Thumbnail Image

Pseudomonas Aeruginosa-Induced Lung Injury - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
From
Loading Indicator

The Respiratory Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs used to treat respiratory diseases. These drugs are used to treat a variety of conditions, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. Commonly prescribed respiratory drugs include bronchodilators, corticosteroids, and antibiotics. The Respiratory Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Companies in the market include GlaxoSmithKline, AstraZeneca, Merck & Co., Novartis, and Boehringer Ingelheim. These companies are constantly researching and developing new drugs to treat respiratory diseases, as well as improving existing treatments. Show Less Read more